Overweight LMT at ~$536 with phased accumulation—initial 1.5% half-position, second tranche on confirmed technical triggers, hard stop $475, trim 1/3 at $597 and $620, run remainder to $674 PT over 3-6 months.
The synthesis of the current debate supports the Research Manager's Overweight with phased accumulation. Record Q2 2026 revenue ($20.06B), record EPS ($7.94), operating margin expansion from 4.1% to 12.4%, $173B+ backlog, $12.15B deferred revenue, 1.75x FCF dividend coverage, and 13-year dividend growth streak provide structural floor. Valuation at 16.4x forward P/E with sub-14x FCF, ~5% total shareholder yield, and PEG ~1.0 supports phased engagement. The 9/4 binding reflection confirmed the structural floor held and "confirmed breakdown" thesis resolved into relief base; honoring prior lessons by rote would reproduce alpha-bleed pathology. Phased accumulation with explicit technical triggers respects the tape without abandoning the thesis.
| Position | Action |
|---|---|
| Initial position at ~$536 | Establish half-position at 1.5% of portfolio |
| $552 reclaim with RSI>50 and contracting MACD | Add remaining half-position |
| Successful $525 retest that holds on declining volume | Add remaining half-position as alternative trigger |
| Price reaches $597 | Trim 1/3 of position |
| Price reaches $620 | Trim 1/3 of position |
| Remainder position | Let run toward $674 UBS PT |
| Total LMT exposure | Cap at 3-4% |
Technical weakness is masking accelerating fundamentals — record earnings, missile super-cycle growth, and NATO spending inflection create an asymmetric entry point at sub-17x forward P/E with a 5% total shareholder yield.
| Indicator | Value | Signal |
|---|---|---|
| Close | $536.15 | neutral |
| Day Range | $532.00 – $541.59 | neutral |
| Volume | 1,315,201 | neutral |
| 10-EMA | $545.40 | bearish |
| 50-SMA | $552.42 | bearish |
| 200-SMA | $550.36 | bearish |
| RSI(14) | 40.48 | bearish |
| MACD | -8.13 | bearish |
| MACD Signal | -2.05 | bearish |
| MACD Histogram | -6.08 | bearish |
| ATR(14) | 13.81 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $552 reclaim with RSI>50 and contracting MACD
Then: Add remaining half-position
Missile super-cycle is structural and backed by signed, funded contracts
↩ rebuts: “Bear's implicit dismissal of missile demand as temporary”
EV: +26% · concedes: Anduril's Polymarket valuation reflects a hot private market for defense technology, indicating sector tailwinds rather than a direct LMT threat
LMT is in a confirmed downtrend with technical deterioration, sector underperformance proving the bull narrative wrong, Anduril eroding prime positions, and macro/political risks creating asymmetric downside — Rating: SELL / AVOID.
EV: $497 (April 2026 low — implies ~7% downside from $536) · concedes: Barron's said it's 'time to buy the dip' (though they noted sector down ~7% and underperforming by ~20pp); Sep 8 bounce after four consecutive down days could signal near-term stabilization; Forward P/E of 16.39x is reasonable on historical basis; Anduril Polymarket odds are 'private market speculation' — not guaranteed; Catalyst that would change view: decisive close above $552 with RSI >50 and MACD histogram contracting
→ vs conservative: Waiting for $552 confirmation is expensive; by the time 50-SMA reclaims cleanly, entry is at $560-plus with same $475 stop, compressing risk-reward materially
→ vs conservative: Technical picture describes the symptom (momentum washout), not the disease (fundamental break); record Q2 numbers and $173B backlog contradict broken thesis
→ vs conservative: ATR of $13.81 is elevated but stop at $475 is not tight; it's a structural stop below April low, not daily noise
→ vs conservative: LMT's 0.104 beta means ATR expansion does not imply dangerous directional whipsaw risk like high-beta stocks
→ vs conservative: Waiting for MACD flip and RSI to reclaim 50 reduces risk by only two to three days of tape noise while costing roughly 3% more on entry
→ vs conservative: Sector underperformance (defense ETF down 7%, underperforming S&P by 20pp) IS the opportunity— Barron's framed it contrarian-bullish for mispricing of structural winner
→ vs conservative: Forward P/E of 16.4 and less than 14x FCF with 2.6% yield do not scream rate sensitivity despite hawkish Fed (6% December cut odds)
→ vs neutral: Holding and watching is playing defense when fundamentals, institutional upgrade cycle, contract momentum, and asymmetric entry all point same direction
→ vs neutral: The technical breakdown is the discount, not a warning—aggressive read is to act now, not after the move has happened
→ vs aggressive: Anduril Polymarket 60% probability of higher private valuation by year-end is a real concern but is a 2030-plus story, not a 2026-2027 trade; $173B backlog, prime-contractor status, F-35 sustainment monopoly, PAC-3 and Javelin franchises not displaced by private-funded competitor in position timeframe
| VWMA (90d) | $555.17 | bearish |
| Bollinger Lower Band | $515.25 | bearish |
| Bollinger Middle Band | $566.52 | neutral |
| Bollinger Upper Band | $617.79 | bearish |
Support: 525.28 · 515 · 497 · 500 | Resistance: 545.4 · 552.42 · 555.17 · 566.52 · 617.79
The technical posture is decisively bearish with price at $536.15 trading under all key moving averages. The Feb 2026 peak of ~$657.84 has corrected sharply, with the April 2026 low at ~$497 establishing major support. Current setup shows first bounce (+2.07% from Sep 4 low of $525.28) after 4 consecutive down-days, but RSI remains sub-50 and MACD histogram deeply negative with no bullish crossover in sight. ATR expanded to $13.81 (from prior $5–$8 range), indicating elevated volatility requiring larger stop buffers. VWMA declining from $571.11 (Aug 1) to $555.17 confirms distribution phase. Key levels to watch: $525.28 support floor below, $552.42 (50-SMA) reclaim = first trend-change signal. Rating: HOLD — too late to short with tight stop, too early to add longs without 50-SMA reclaim.
Market Cap
$123.7B
P/E (TTM)
19.78x
Forward P/E
16.39x
PEG Ratio
1.0
Price/Book
14.06x
EPS (TTM)
$27.10
Forward EPS
$32.72
Beta
0.104
Dividend Yield
2.63%
52-Week High
$692.00
52-Week Low
$437.25
50-Day Avg
$554.93
200-Day Avg
$556.86
Operating Margin
11.96%
Net Margin
8.16%
ROE
89.2%
ROA
8.64%
Net Debt
$16.75B
Debt/Equity
234%
Net Debt/EBITDA
~1.73x
Current Ratio
1.19
FCF (TTM)
$5.56B
Revenue TTM
$77.0B
Net Income TTM
$6.29B
Q2'26 Revenue
$20.06B
Q2'26 Operating Income
$2.48B
Q2'26 Net Income
$1.84B
Q2'26 Diluted EPS
$7.94
Q2'26 FCF
$2.92B
FY2025 Revenue
$75.05B
FY2025 Gross Profit
$7.62B
FY2025 Operating Income
$7.73B
FY2025 EBITDA
$8.73B
FY2025 Net Income
$5.02B
FY2025 Diluted EPS
$21.49
FY2025 Diluted Shares
233.5M
FY2024 Revenue
$71.04B
FY2024 Net Income
$5.34B
FY2024 Diluted EPS
$22.31
FY2023 Revenue
$67.57B
FY2023 Net Income
$6.92B
FY2023 Diluted EPS
$27.55
FY2022 Revenue
$65.98B
FY2022 Net Income
$5.73B
FY2022 Diluted EPS
$21.66
FY2025 Total Assets
$59.84B
FY2025 Total Debt
$21.70B
Backlog
$173B+
Interest Expense FY2025
$1.12B
Shares Repurchased
~30M shares
Shareholder Yield
~5.0%
Strengths
Concerns
Lockheed Martin is the world's largest defense contractor with a $173B+ backlog providing multi-year revenue visibility across Aeronautics (F-35, F-22), Missiles and Fire Control (PAC-3, THAAD), Rotary and Mission Systems, and Space segments. The company delivered record Q2 2026 results with revenue of $20.06B and EPS of $7.94, both all-time highs, while aggressively deleveraging net debt by $3.6B to $16.75B. Despite premium valuation (forward P/E 16.4x) and high leverage (debt/equity 234%), the company benefits from secular defense spending tailwinds, robust FCF generation ($5.56B TTM), and a 5% total shareholder yield through dividends and buybacks.
Macro: Macro backdrop is mixed: Polymarket-implied Fed rate cut probabilities are 0% by September 2026, 4% by October 2026, and only 6% by December 2026 (down 4pp in one week), with markets pricing the next move as a hike rather than a cut — creating rate headwind for long-duration defense equities. Geopolitically, the Iran conflict (active since late February 2026) with US sanctions on 27 Iranian airlines is positive for defense backlog but negative for broader risk appetite. Russia-Ukraine war ongoing with HIMARS demand from European buyers. Canada retaliatory tariffs and rising oil prices signal broader risk-off. Polymarket niche signal shows Anduril at 60% probability of higher valuation than LMT by Dec 31 (up 19pp weekly), pricing a credible long-term competitive threat from a well-funded tech-defense entrant.